Biomarkers are like the X on a treasure map, but instead of indicating the location of unearthed riches, they indicate an individual’s health status.
Common biomarkers include certain RNA or protein molecules present in tissues and body fluids that can show doctors that a patient has a specific disease or may respond well to a particular treatment plan.
Liquid biopsies are appealing as a non-invasive method for measuring biomarker levels in a body fluid.
In a recent article published in Annals of Surgery, a team led by researchers at Tokyo Medical and Dental University (TMDU) report how they designed such a method for predicting patient outcomes following treatment for oesophageal squamous cell carcinoma (ESCC).
ESCC is an aggressive and deadly disease.
Data from the United States suggest that its 5-year overall survival rate is less than 20%.
Surgery is the typical treatment method, but recently researchers have shown that adding neoadjuvant therapy (NAT) can improve patient survival rates.
NAT involves shrinking a tumour using approaches such as chemotherapy or radiation prior to surgery.
However, not all patients are responsive to NAT.
Unnecessarily performing it can patient time for these patients and lead to worse outcomes.
Therefore, the TMDU group aimed to identify biomarkers and characteristics that could preemptively indicate an ESCC patient’s response to NAT.
“Molecular biomarkers can be extremely useful when making clinical decisions,” says lead author of the study Keisuke Okuno. “We also wanted to translate these biomarkers into an easy-to-use liquid biopsy.”
To do this, the team obtained 128 ESCC tissue samples and 58 matched serum samples from two clinical institutions.
The serum was obtained prior to any treatment.
NAT for these patients involved chemotherapy with 5-fluorouracil and cisplatin, followed by surgery 3 to 5 weeks later.
Pathologists then analysed the surgical specimens for residual tumour cells, which helped them categorise these ESCC patients as completely, partially, or non-responsive to NAT.
“We then examined these patient samples for expression levels of molecules that included three mRNAs and four microRNAs,” states Ajay Goel, senior author of the article. “In previous studies, this panel of mRNAs and microRNAs was found to effectively predict ESCC patient response to NAT.”
After the TMDU group analysed their data, they concluded that their panel of mRNAs and microRNAs had significant predictive potential.
Interestingly, combining the panel with tumour size data further increased the predictive power.
mRNA/microRNA signature was the most effective clinical characteristic amongst various combinations.
It worked in both early- and advanced-stage ESCC patients.
“We then utilised the pre-treatment serum samples to translate this signature into a liquid biopsy assay, and our approach still maintained its strong ability to predict response to NAT,” explains Okuno.
Overall, the liquid biopsy developed by this team may serve as a non-invasive method for predicting ESCC patient response to NAT.
This can lead to precision medicine approaches that will significantly improve the prognosis of many patients who have this disease.